miRNA定序和检测市场－全球产业规模、份额、趋势、机会和预测（按技术、应用、最终用途、工作流程、地区和竞争格局划分，2021-2031年）

全球微型RNA定序和检测市场预计将从2025年的242.6亿美元成长到2031年的355.6亿美元，复合年增长率为6.58%。

这些基因组技术涉及检测和定量小型非编码RNA分子的方法，这些分子在基因表现调控中发挥关键作用。这一市场趋势的主要驱动力是慢性疾病（包括癌症）的日益增多，这催生了对先进生物标记发现工具的强劲需求，这些工具对于早期诊断和患者分层至关重要。此外，精准医疗倡议的广泛实施和基因组研究经费的不断增加也为该领域的发展提供了重要动力。

儘管有这些正面趋势，但该产业在分析通讯协定标准化方面仍面临重大挑战，导致不同平台间的资料可重复性难以保证。这种技术差异性严重阻碍了其在临床上的广泛应用和监管核准。美国癌症协会估计，到2024年，美国将新增约2,001,140例癌症病例，凸显了此类诊断能力的重要性。因此，解决一致性问题对于满足应对日益增长的癌症负担的诊断需求至关重要。

市场驱动因素

全球miRNA定序和检测市场的成长主要受全球癌症和慢性疾病发生率上升的驱动，这促使人们需要能够实现早期检测和病患监测的非侵入性生物标记。由于miRNA在生物体液中稳定，因此它们在诊断流程中的应用日益广泛，有助于改善临床疗效。世界卫生组织（WHO）下属的国际癌症研究机构（IARC）也支持这项日益增长的需求。在2024年2月题为《全球癌症负担日益加重》的新闻稿中，该机构预测到2050年，全球新增癌症病例将超过3500万例，比2022年增长77%。这些预测凸显了扩充性定序解决方案的必要性，以应对复杂疾病的大规模诊断筛检。

同时，公共和私人对基因组研究的资金投入激增，加速了基于液态生物检体的诊断技术的进步。这笔资金的涌入使生物技术公司能够提高检测的灵敏度并检验其临床效用，从而有效降低了市场准入门槛。例如，Freenome在2024年2月发布的公告「Freenome融资2.54亿美元推进早期癌症检测」中宣布，资金筹措2.54亿美元用于扩大筛检平台的覆盖范围。此外，技术扩充性是此生态系的关键组成部分。 Illumina在2024年报告称，其上一财年共交付了352台NovaSeq X测序仪，这表明该行业已具备坚实的基础，能够支持现代基因组检测对高通量日益增长的需求。

市场挑战

全球miRNA定序和检测市场发展的主要障碍之一是缺乏标准化的分析通讯协定。不同的实验室采用不同的工作流程、撷取方法和定序平台，常常导致数据不一致。这种技术差异使得结果的可重复性难以保证，而可重复性是临床应用的基本要求，同时也阻碍了相关人员有效比较不同研究的结果。因此，医疗机构往往不愿意将这些检测方法应用于常规患者照护，阻碍了其广泛应用。

这种碎片化也直接影响监管结果和商业性可行性，因为监管机构要求强有力的分析有效性证据。数据不一致会显着延缓新诊断工具的核准流程，并限制可靠检测手段的可用性，进而影响现代治疗方法。个人化医疗联盟在2024年发布的数据凸显了这个问题的迫切性，该联盟预测，2023年核准的新药中将有35%与个人化医疗相关。无法对这些治疗方法的检测方法进行标准化，限制了其收入潜力，并阻碍了整个微型RNA定序领域的扩张。

市场趋势

将人工智慧融入miRNA生物标记发现领域，正从根本上重塑市场格局，使其能够快速识别传统分析方法往往忽略的复杂疾病特征。先进的演算法如今可以处理海量多组体学资料集，并高精度地预测miRNA标靶，加速诊断试剂盒的开发。这项技术变革正得到各大运算公司的积极支持，他们提供了必要的基础设施。例如，在2024年3月发布的题为「NVIDIA Healthcare发布生成式AI微服务，助力药物研发、医疗技术和数位健康」的新闻稿中，NVIDIA推出了20多项新的微服务，用于在医疗机构部署生成式AI模型。这些工具能够帮助研究人员有效地分析基因组数据，并显着缩短检验潜在miRNA候选物用于临床应用所需的时间。

同时，单细胞miRNA定序的日益普及正在推动市场扩张，因为它能够解析细胞异质性，而这种异质性通常会被批量定序所掩盖。这种精细化的方法在肿瘤学领域尤其重要，因为了解肿瘤微环境中不同细胞群的特异性miRNA谱对于开发标靶治疗至关重要。製造商们正透过提供降低经济门槛的低成本平台来支持这项变革。 10x Genomics在2024年10月的2024年第三季公布财报上确认了其GEM-X Flex和Universal Multiplex Assays的出货情况，这正体现了这一趋势，使研究人员能够以每个细胞不到1美分的成本分析数百万个细胞。诸如此类的创新对于将单细胞分析从小众学术研究领域推广到更广泛的临床应用至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球miRNA定序与检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（合成定定序、寡核苷酸连接检测 (SOLiD)、奈米孔定序、桑格定序、单分子即时 (SMRT)定序）
  • 依应用领域（癌症、麸胺酸紊乱、自体免疫疾病、思觉失调症等）
  • 按最终用途（製药和生物技术行业、研究和学术机构、其他）
  • 按工作流程（样品製备、定序、资料分析和储存）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美miRNA定序与检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲miRNA定序与检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区miRNA定序与检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲 miRNA定序和检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲 miRNA定序与检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球miRNA定序与检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• QIAGEN NV
• PerkinElmer, Inc.
• Abcam plc
• New England Biolabs, Inc.
• Takara Bio USA Inc.
• Lexogen GmbH
• Norgen Biotek Corp.
• Maravai LifeSciences Holdings, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global MiRNA Sequencing and Assay Market is projected to expand from USD 24.26 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 6.58%. These genomic technologies encompass methods designed to detect and quantify small non-coding RNA molecules that play a crucial role in regulating gene expression. This market trajectory is primarily driven by the increasing prevalence of chronic conditions, particularly cancer, which creates a strong demand for advanced biomarker discovery tools essential for early diagnosis and patient stratification. Additionally, the broader implementation of precision medicine initiatives and increased funding for genomic research provide substantial momentum for the sector's growth.

Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.

Market Driver

The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.

Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.

Market Challenge

A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.

This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.

Market Trends

The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels. This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.

Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies. Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• QIAGEN N.V.
• PerkinElmer, Inc.
• Abcam plc
• New England Biolabs, Inc.
• Takara Bio USA Inc.
• Lexogen GmbH
• Norgen Biotek Corp.
• Maravai LifeSciences Holdings, Inc

Report Scope

In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

MiRNA Sequencing and Assay Market, By Technology

• Sequencing by Synthesis
• Sequencing by Oligonucleotide Ligation and Detection (SOLiD)
• Nanopore Sequencing
• Sanger Sequencing
• Single Molecule Real-time (SMRT) Sequencing

MiRNA Sequencing and Assay Market, By Application

• Cancer
• Polyglutamine Diseases
• Autoimmune Disease
• Schizophrenia
• Others

MiRNA Sequencing and Assay Market, By End-use

• Pharmaceutical & Biotechnology Industry
• Research and Academic Institutes
• Others

MiRNA Sequencing and Assay Market, By Workflow

• Library Preparation
• Sequencing
• Data Analysis & Storage

MiRNA Sequencing and Assay Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.

Available Customizations:

Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global MiRNA Sequencing and Assay Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing)
  • 5.2.2. By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others)
  • 5.2.3. By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others)
  • 5.2.4. By Workflow (Library Preparation, Sequencing, Data Analysis & Storage)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America MiRNA Sequencing and Assay Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Workflow
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States MiRNA Sequencing and Assay Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
      • 6.3.1.2.4. By Workflow
  • 6.3.2. Canada MiRNA Sequencing and Assay Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
      • 6.3.2.2.4. By Workflow
  • 6.3.3. Mexico MiRNA Sequencing and Assay Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use
      • 6.3.3.2.4. By Workflow

7. Europe MiRNA Sequencing and Assay Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Workflow
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany MiRNA Sequencing and Assay Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
      • 7.3.1.2.4. By Workflow
  • 7.3.2. France MiRNA Sequencing and Assay Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
      • 7.3.2.2.4. By Workflow
  • 7.3.3. United Kingdom MiRNA Sequencing and Assay Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
      • 7.3.3.2.4. By Workflow
  • 7.3.4. Italy MiRNA Sequencing and Assay Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
      • 7.3.4.2.4. By Workflow
  • 7.3.5. Spain MiRNA Sequencing and Assay Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use
      • 7.3.5.2.4. By Workflow

8. Asia Pacific MiRNA Sequencing and Assay Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Workflow
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China MiRNA Sequencing and Assay Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
      • 8.3.1.2.4. By Workflow
  • 8.3.2. India MiRNA Sequencing and Assay Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
      • 8.3.2.2.4. By Workflow
  • 8.3.3. Japan MiRNA Sequencing and Assay Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
      • 8.3.3.2.4. By Workflow
  • 8.3.4. South Korea MiRNA Sequencing and Assay Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
      • 8.3.4.2.4. By Workflow
  • 8.3.5. Australia MiRNA Sequencing and Assay Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use
      • 8.3.5.2.4. By Workflow

9. Middle East & Africa MiRNA Sequencing and Assay Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Workflow
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia MiRNA Sequencing and Assay Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
      • 9.3.1.2.4. By Workflow
  • 9.3.2. UAE MiRNA Sequencing and Assay Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
      • 9.3.2.2.4. By Workflow
  • 9.3.3. South Africa MiRNA Sequencing and Assay Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use
      • 9.3.3.2.4. By Workflow

10. South America MiRNA Sequencing and Assay Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Workflow
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil MiRNA Sequencing and Assay Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
      • 10.3.1.2.4. By Workflow
  • 10.3.2. Colombia MiRNA Sequencing and Assay Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
      • 10.3.2.2.4. By Workflow
  • 10.3.3. Argentina MiRNA Sequencing and Assay Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use
      • 10.3.3.2.4. By Workflow

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global MiRNA Sequencing and Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. QIAGEN N.V.
• 15.4. PerkinElmer, Inc.
• 15.5. Abcam plc
• 15.6. New England Biolabs, Inc.
• 15.7. Takara Bio USA Inc.
• 15.8. Lexogen GmbH
• 15.9. Norgen Biotek Corp.
• 15.10. Maravai LifeSciences Holdings, Inc

16. Strategic Recommendations

17. About Us & Disclaimer